aTYR PHARMA INC Other General and Administrative Expense
aTYR PHARMA INC (ATYR) reported Other General and Administrative Expense of $3.23 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherGeneralAndAdministrativeExpense · last filed 2026-08-07
- aTYR PHARMA INC other general and administrative expense for the quarter ending 2026-06-30 was $3.23M, a 17.72% decline year-over-year.
- aTYR PHARMA INC other general and administrative expense for the quarter ending 2026-03-31 was $3.08M, a 0.39% increase year-over-year.
- aTYR PHARMA INC other general and administrative expense for the quarter ending 2025-12-31 was $2.85M, a 2.60% decline year-over-year.
- aTYR PHARMA INC other general and administrative expense for the quarter ending 2025-09-30 was $3.89M, a 38.86% increase year-over-year.
- aTYR PHARMA INC other general and administrative expense for fiscal 2025 was $13.73M, a 20.42% increase from fiscal 2024.
- aTYR PHARMA INC other general and administrative expense for fiscal 2024 was $11.40M, a 4.50% increase from fiscal 2023.
- aTYR PHARMA INC other general and administrative expense for fiscal 2023 was $10.91M, a 11.54% decline from fiscal 2022.
- aTYR PHARMA INC other general and administrative expense for fiscal 2022 was $12.33M.
| Period end | Other General and Administrative Expense 3 month | Other General and Administrative Expense 6 month | Other General and Administrative Expense 9 month | Other General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.23M 10-Q · filed 2026-08-07 | $6.31M 10-Q · filed 2026-08-07 | $9.16M derived: sum of 3 quarters · filed 2026-08-07 | $13.05M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $3.08M 10-Q · filed 2026-05-15 | $5.93M derived: sum of 2 quarters · filed 2026-05-15 | $9.81M derived: sum of 3 quarters · filed 2026-05-15 | $13.74M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $6.74M derived: sum of 2 quarters · filed 2026-03-05 | $10.67M derived: sum of 3 quarters · filed 2026-08-07 | $13.73M 10-K · filed 2026-03-05 |
| 2025-09-30 | $3.89M 10-Q · filed 2025-11-06 | $7.82M derived: sum of 2 quarters · filed 2026-08-07 | $10.88M 10-Q · filed 2025-11-06 | $13.81M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $3.93M 10-Q · filed 2026-08-07 | $6.99M 10-Q · filed 2026-08-07 | $9.92M derived: sum of 3 quarters · filed 2026-08-07 | $12.72M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $3.06M 10-Q · filed 2026-05-15 | $5.99M derived: sum of 2 quarters · filed 2026-05-15 | $8.79M derived: sum of 3 quarters · filed 2026-05-15 | $11.55M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $2.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $5.73M derived: sum of 2 quarters · filed 2026-03-05 | $8.49M derived: sum of 3 quarters · filed 2026-03-05 | $11.40M 10-K · filed 2026-03-05 |
| 2024-09-30 | $2.80M 10-Q · filed 2025-11-06 | $5.56M derived: sum of 2 quarters · filed 2025-11-06 | $8.48M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $2.76M 10-Q · filed 2025-08-07 | $5.68M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $2.92M 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $10.91M 10-K · filed 2026-03-05 | |||
| 2022-12-31 | $12.33M 10-K · filed 2025-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |